https://www.live-feeds.com/feed/j-j-is-in-talks-to-sell-its-hips-and-knees-business-to-apollo-for-20-billionContinuously updated, source-cited coverage. https://www.live-feeds.com/feed/j-j-is-in-talks-to-sell-its-hips-and-knees-business-to-apollo-for-20-billionhttps://www.live-feeds.com/feed/j-j-is-in-talks-to-sell-its-hips-and-knees-business-to-apollo-for-20-billion#u68928Tue, 15 Sep 2026 11:31:34 +0000Johnson & Johnson is engaged in discussions with Apollo Global Management to sell its DePuy Synthes orthopedics business in a transaction valued at nearly $20 billion. The potential divestiture of the medical device unit pushed Johnson & Johnson shares up 1.3% to $268.96 in premarket trading on Monday following reports from Bloomberg News citing people familiar with the matter. The orthopedics division generated $9.3 billion in revenue last year. Alternatively, the unit could be spun off as a public company, though specific deal terms remain unfinalized and negotiations are ongoing bet https://www.live-feeds.com/feed/j-j-is-in-talks-to-sell-its-hips-and-knees-business-to-apollo-for-20-billionhttps://www.live-feeds.com/feed/j-j-is-in-talks-to-sell-its-hips-and-knees-business-to-apollo-for-20-billion#u67612Mon, 14 Sep 2026 07:45:38 +0000Johnson & Johnson is engaged in discussions to sell its hips-and-knees orthopedics business to Apollo Global Management in a transaction valued at $20 billion. The potential divestiture involves the medical device giant's major orthopedic unit, drawing interest from private equity. Financial markets reacted to the reports in after-hours trading, pushing shares of Johnson & Johnson up slightly following the news of the talks. Negotiations remain ongoing between the companies, and specific deal terms have not yet been finalized.Why it mattersJohnson & Johnson has been continuous